Giovanni Musso | Medicine and Dentistry | Best Researcher Award

AOU San Luigi Gonzaga Orbassano (Torino), Italy

Dr. Giovanni Musso is a renowned clinician and researcher in Internal Medicine with a distinguished academic and professional career. He graduated in Medicine in 1996 with top honors (110/110) and completed his specialization in Internal Medicine in 2002 with distinction. Currently serving at the Department of Internal Medicine, Humanitas Gradenigo Hospital, Turin, he has devoted his career to the study of lipid and glucose metabolism, with particular emphasis on non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), and related metabolic complications. He leads international collaborative research involving 34 centers worldwide, producing high-impact findings on NAFLD epidemiology, pathogenesis, and staging, with publications in PLOS Medicine, Hepatology, Gastroenterology, BMJ, and other leading journals. His research interests include lipidomics, postprandial metabolism, gut microbiota, metabolic inflammation, and therapeutic innovations such as curcumin-based interventions and endoscopic approaches for metabolic disorders. His research skills span clinical trials, meta-analyses, translational studies, and consensus guideline development. Recognized globally, Dr. Musso has authored 101 documents, accrued 12,017 citations, and holds an impressive h-index of 49 (Sept 2025). His honors include co-authoring international consensus statements and leading global research collaborations. With his proven excellence in research, teaching, and clinical innovation, Dr. Musso continues to advance the field of hepatology and metabolic medicine while shaping future directions in precision healthcare.

Profile: Scopus | ORCID

Featured Publications

• Musso, G., Mariano, F., Mella, A., Pinach, S., & Gambino, R. (2025, August 7). Meal-Induced NF-κB Activation in Mononuclear Cells Triggers Lumican Secretion and Promotes Chronic Kidney Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease. MedComm, 6(8), e70122.

• Carpenito, N., Leporati, M., Sciarrillo, A., Pensa, A., Gambino, R., Musso, G., Mella, A., Biancone, L., Risso, D., Mariano, F., & Cosseddu, D. (2025, May 16). LC-MS/MS Determination of Quorum Sensing Molecules in Plasma from Burn Patients with Septic Shock Sustained by Acinetobacter baumannii. Antibiotics (Basel), 14(5), 517.

• Musso, G., Mella, A., Mariano, F., Cassader, M., De Michieli, F., Riva, A., Petrangolini, G., Togni, S., Pinach, S., & Gambino, R. (2024). Impaired Postprandial GLP-2 Response Enhances Endotoxemia, Systemic Inflammation, and Kidney Injury in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Effect of Phospholipid Curcumin Meriva. Gut Microbes, 16(1), article 2424907.

• Musso, G., Pinach, S., Mariano, F., Saba, F., De Michieli, F., Framarin, L., Berrutti, M., Paschetta, E., Parente, R., Lizet Castillo, Y., Leone, N., Castellino, F., Cassader, M., & Gambino, R. (2025, February 1). Effect of Phospholipid Curcumin Meriva® on Liver Histology and Kidney Disease in Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial. Hepatology, 81(2), 560–575.

• Musso, G., Pinach, S., Saba, F., De Michieli, F., Cassader, M., & Gambino, R. (2024, July). Endoscopic Duodenal Mucosa Ablation Techniques for Diabetes and Nonalcoholic Fatty Liver Disease